ATE169822T1 - Behandlung von herpesvirus infektion - Google Patents

Behandlung von herpesvirus infektion

Info

Publication number: ATE169822T1
Authority: AT; Austria
Prior art keywords: treatment; herpesvirus infection; herpesviruses; oligopeptide; preferred
Prior art date: 1992-04-23

Application number

AT93911414T

Other languages

English (en)

Inventor

Michael Twist

Richard W Barnett

Martin Summer-Smith

Lorne S Reid

Original Assignee

Allelix Biopharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-04-23

Filing date

1993-04-21

Publication date

1998-09-15

1993-04-21 Application filed by Allelix Biopharma filed Critical Allelix Biopharma

1998-09-15 Application granted granted Critical

1998-09-15 Publication of ATE169822T1 publication Critical patent/ATE169822T1/de

Links

208000029433 Herpesviridae infectious disease Diseases 0.000 title 1
102000015636 Oligopeptides Human genes 0.000 abstract 2
108010038807 Oligopeptides Proteins 0.000 abstract 2
ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 abstract 1
229930028154 D-arginine Natural products 0.000 abstract 1
241000700584 Simplexvirus Species 0.000 abstract 1
210000004899 c-terminal region Anatomy 0.000 abstract 1
125000006239 protecting group Chemical group 0.000 abstract 1
230000010076 replication Effects 0.000 abstract 1
241001529453 unidentified herpesvirus Species 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

AT93911414T 1992-04-23 1993-04-21 Behandlung von herpesvirus infektion ATE169822T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US87239892A	1992-04-23	1992-04-23

Publications (1)

Publication Number	Publication Date
ATE169822T1 true ATE169822T1 (de)	1998-09-15

Family

ID=25359492

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93911414T ATE169822T1 (de)	1992-04-23	1993-04-21	Behandlung von herpesvirus infektion

Country Status (7)

Country	Link
EP (1)	EP0637247B1 (de)
JP (1)	JPH08501060A (de)
AT (1)	ATE169822T1 (de)
AU (1)	AU4037793A (de)
CA (1)	CA2134119A1 (de)
DE (1)	DE69320469D1 (de)
WO (1)	WO1993021941A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5633230A (en) *	1990-10-24	1997-05-27	Allelix Biopharmaceuticals, Inc.	Treatment of cytomegalovirus infection
CA2152373C (en) *	1993-10-22	1998-12-15	Michael Twist (Deceased)	Treatment of cytomegalovirus infection
DE19520792A1 (de) *	1995-06-07	1996-12-12	Bloch Wilhelm Dr	Verwendung der Stickstoffmonoxidsynthese hemmenden Substanzen der Gruppe der L-Argininanaloge zur Herstellung eines Mittels zur Abschwellung entzündlich bzw. allergisch angeschwollener Nasenschleimhaut und der Hemmung entzündlich und allergisch bedingter Nasensekretion
IL132941A0 (en)	1997-05-21	2001-03-19	Univ Leland Stanford Junior	Composition and method for enhancing transport across biological membranes
US6919076B1 (en)	1998-01-20	2005-07-19	Pericor Science, Inc.	Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en)	1998-01-20	2005-10-25	Pericor Science, Inc.	Linkage of agents to body tissue using microparticles and transglutaminase
EP1656945A1 (de) *	1999-06-05	2006-05-17	The Board Of Trustees Of The Leland Stanford Junior University	Pharmazeutische Zusammensetzung enthaltend Oligoarginin
US6730293B1 (en)	1999-08-24	2004-05-04	Cellgate, Inc.	Compositions and methods for treating inflammatory diseases of the skin
US6669951B2 (en)	1999-08-24	2003-12-30	Cellgate, Inc.	Compositions and methods for enhancing drug delivery across and into epithelial tissues
CA2381425A1 (en)	1999-08-24	2001-03-01	Cellgate, Inc.	Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en)	1999-08-24	2007-06-12	Cellgate, Inc.	Compositions and methods for enhancing drug delivery across and into ocular tissues
US7033991B2 (en) *	2001-07-16	2006-04-25	Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College	Inhibiting furin with polybasic peptides
CN101842107B (zh) *	2007-07-26	2014-04-23	雷文斯治疗公司	抗微生物肽，组合物和使用方法
ES2444299B1 (es)	2012-08-23	2014-12-12	Nutrición Técnica Deportiva, S.L.	Uso de un hidrolizado de caseina como agente antiherpético

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1989012461A1 (en) *	1988-06-16	1989-12-28	St. Louis University	Antagonists of viral transactivating proteins
EP0554284B1 (de) *	1990-10-24	1996-12-18	Allelix Biopharmaceuticals Inc.	Peptidische hemmer der hiv-replikation

1993
- 1993-04-21 EP EP93911414A patent/EP0637247B1/de not_active Expired - Lifetime
- 1993-04-21 AU AU40377/93A patent/AU4037793A/en not_active Abandoned
- 1993-04-21 JP JP5518785A patent/JPH08501060A/ja active Pending
- 1993-04-21 CA CA002134119A patent/CA2134119A1/en not_active Abandoned
- 1993-04-21 WO PCT/CA1993/000166 patent/WO1993021941A1/en not_active Ceased
- 1993-04-21 DE DE69320469T patent/DE69320469D1/de not_active Expired - Lifetime
- 1993-04-21 AT AT93911414T patent/ATE169822T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69320469D1 (de)	1998-09-24
JPH08501060A (ja)	1996-02-06
AU4037793A (en)	1993-11-29
CA2134119A1 (en)	1993-11-11
EP0637247B1 (de)	1998-08-19
EP0637247A1 (de)	1995-02-08
WO1993021941A1 (en)	1993-11-11

Similar Documents

Publication	Publication Date	Title
GR3022838T3 (en)	1997-06-30	Peptide-based inhibitors of hiv replication
ATE169822T1 (de)	1998-09-15	Behandlung von herpesvirus infektion
DK0973735T3 (da)	2003-06-23	Polyaromatiske antivirale præparater
ATE303993T1 (de)	2005-09-15	4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
CA2293470A1 (en)	1998-12-17	Benzimidazole derivatives
NO953371D0 (no)	1995-08-28	Anvendelse av anti-konvulsiva ved behandling av neuro-AIDS
DE69131200D1 (en)	1999-06-10	Herpes simplex virus vp16 impfstoffe
MX9308005A (es)	1994-08-31	Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
DE69125262D1 (de)	1997-04-24	Synergische Mischung zur Behandlung von Herpes
EA199800526A1 (ru)	1999-04-29	Производные бензимидазола и их применение для лечения вирусных инфекций
DE69330268D1 (de)	2001-07-05	Hämoregulierende peptide
DE69004451D1 (de)	1993-12-16	Prophylaxe und Behandlung von Herpesvirus-Infektionen.
DE69608959D1 (de)	2000-07-27	Chlamydia impfstoffen
ES2101747T3 (es)	1997-07-16	Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
ATE189460T1 (de)	2000-02-15	Gegen protozoen wirksamezyklische tetrapeptide
ITMI913493A1 (it)	1993-06-27	Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus
UA41338C2 (uk)	2001-09-17	Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
ES2073286T3 (es)	1995-08-01	Productos cosmeticos estables.
MC2306A1 (fr)	1993-09-27	Peptides bloquant les infections par le virus de l'immunodeficience humaine et methode de leur utilisation
ATE255417T1 (de)	2003-12-15	Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69231465D1 (de)	2000-10-26	Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ES2078380T3 (es)	1995-12-16	Oligofosfatos de accion antiviral.
ES2062266T3 (es)	1994-12-16	Uso de quinolil- e isoquinoliloxazol-2-onas para la obtencion de un medicamento destinado para la prevencion de infecciones por virus envueltos por glicoproteinas.
RU93045696A (ru)	1996-04-27	Ингибиторы протеазы вируса иммунодефицита человека, полезные для лечения спида
ES2068739A1 (es)	1995-04-16	Inhibidores retrovirables de proteasas.

Legal Events

Date	Code	Title	Description
1999-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties